Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of adjuvant giredestrant versus physician's choice endocrine therapy in ER-positive, HER2-negative early breast cancer
MOH_2021-07-11_010102Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of giredestrant in breast cancer (2 arms), sponsored by Roche. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2021-07-11_010102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-11_010102.